Clinical Trial Detail

NCT ID NCT01877811
Title CEP-32496 in Patients With Advanced Solid Tumors in Phase 1 and Advanced Melanoma and Metastatic Colorectal Cancer in Phase 2
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Teva Pharmaceutical Industries
Indications

lung squamous cell carcinoma

lung adenocarcinoma

Advanced Solid Tumor

Therapies

RXDX-105

Age Groups: adult senior

Additional content available in CKB BOOST